EA201690170A1 - Композиции и способы для лечения инсульта - Google Patents

Композиции и способы для лечения инсульта

Info

Publication number
EA201690170A1
EA201690170A1 EA201690170A EA201690170A EA201690170A1 EA 201690170 A1 EA201690170 A1 EA 201690170A1 EA 201690170 A EA201690170 A EA 201690170A EA 201690170 A EA201690170 A EA 201690170A EA 201690170 A1 EA201690170 A1 EA 201690170A1
Authority
EA
Eurasian Patent Office
Prior art keywords
stroke
ischemic stroke
methods
treatment
compositions
Prior art date
Application number
EA201690170A
Other languages
English (en)
Inventor
Барри Тайко
Якоб Элкинс
Original Assignee
Байоджен Ма Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байоджен Ма Инк. filed Critical Байоджен Ма Инк.
Publication of EA201690170A1 publication Critical patent/EA201690170A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Изобретение относится, inter alia, к способам лечения инсульта, например ишемического инсульта, например острого ишемического инсульта, и способам уменьшения размера инфаркта и/или других неврологических нарушений, связанных с инсультом, например ишемическим инсультом, например острым ишемическим инсультом, в которых применяется антагонист VLA-4, такой как натализумаб. Было обнаружено, что антагонисты VLA-4, такие как натализумаб, могут эффективно уменьшать размер инфаркта и других неврологических нарушений при инсульте, например ишемическом инсульте, например остром ишемическом инсульте, например, при введении в течение определенного периода после начала инсульта. Также в данном документе раскрыты изделия и наборы для лечения инсульта, например ишемического инсульта, например острого ишемического инсульта.
EA201690170A 2013-07-05 2014-07-03 Композиции и способы для лечения инсульта EA201690170A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361843125P 2013-07-05 2013-07-05
PCT/US2014/045457 WO2015003156A1 (en) 2013-07-05 2014-07-03 Compositions and methods for treatment of stroke

Publications (1)

Publication Number Publication Date
EA201690170A1 true EA201690170A1 (ru) 2016-05-31

Family

ID=52144219

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690170A EA201690170A1 (ru) 2013-07-05 2014-07-03 Композиции и способы для лечения инсульта

Country Status (13)

Country Link
US (1) US20160152709A1 (ru)
EP (1) EP3016981A4 (ru)
JP (1) JP2016523931A (ru)
KR (1) KR20160030200A (ru)
CN (1) CN105658667A (ru)
AU (1) AU2014285086A1 (ru)
CA (1) CA2916028A1 (ru)
EA (1) EA201690170A1 (ru)
HK (1) HK1217715A1 (ru)
IL (1) IL243265A0 (ru)
MX (1) MX2015017467A (ru)
WO (1) WO2015003156A1 (ru)
ZA (1) ZA201509360B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2034830T3 (pl) * 2006-05-25 2015-04-30 Biogen Ma Inc Przeciwciało anty-VLA-1 do leczenia udaru
WO2017015544A1 (en) * 2015-07-23 2017-01-26 Biogen Ma Inc. Compositions and methods for treatment of stroke and other cns disorders
WO2018140510A1 (en) * 2017-01-25 2018-08-02 Biogen Ma Inc. Compositions and methods for treatment of stroke and other cns disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2258400A3 (en) * 2004-07-08 2011-08-10 Elan Pharmaceuticals, Inc. Multivalent VLA-4 antagonists comprising polymer moieties
EP1827491A4 (en) * 2004-11-19 2010-07-14 Biogen Idec Inc TREATMENT OF MULTIPLE SCLEROSIS
PL2034830T3 (pl) * 2006-05-25 2015-04-30 Biogen Ma Inc Przeciwciało anty-VLA-1 do leczenia udaru
US8771689B2 (en) * 2006-12-11 2014-07-08 The Board Of Trustees Of The Leland Stanford Junior University Alpha B-crystallin as a therapy for ischemia or inflammation
EP2050462A1 (en) * 2007-10-18 2009-04-22 PAION Deutschland GmbH Improved treatment of stroke patients
PT3202789T (pt) * 2010-04-16 2020-06-16 Biogen Ma Inc Anticorpos anti-vla-4
AU2012325013A1 (en) * 2011-10-17 2014-03-27 Westfaelische Wilhelms-Universitaet Muenster Methods of risk assessment of PML and related apparatus

Also Published As

Publication number Publication date
CN105658667A (zh) 2016-06-08
CA2916028A1 (en) 2015-01-08
IL243265A0 (en) 2016-03-31
EP3016981A1 (en) 2016-05-11
WO2015003156A1 (en) 2015-01-08
HK1217715A1 (zh) 2017-01-20
ZA201509360B (en) 2018-07-25
JP2016523931A (ja) 2016-08-12
MX2015017467A (es) 2016-04-25
KR20160030200A (ko) 2016-03-16
AU2014285086A1 (en) 2016-01-21
US20160152709A1 (en) 2016-06-02
EP3016981A4 (en) 2017-05-31

Similar Documents

Publication Publication Date Title
AU2018236800B2 (en) DNA-PK inhibitors
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
PH12016501600A1 (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
TN2017000134A1 (en) 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer's disease
PH12015502075B1 (en) Treatment of cataplexy
MX2017016424A (es) Compuestos para su uso en el tratamiento de trastornos neuromusculares.
WO2015168532A3 (en) Compositions and methods for modulating pkk expression
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
MX362185B (es) Composiciones y tratamiento para enfermedades y trastornos del ojo.
EA201891251A1 (ru) Бициклические ингибиторы pad4
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
MX2018012902A (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
WO2016094834A3 (en) A method for treating a complement mediated disorder caused by an infectious agent in a patient
PH12015501566A1 (en) Methods of treatment of fibrosis and cancers
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
EA201690170A1 (ru) Композиции и способы для лечения инсульта
MX2020011766A (es) Metodos de administracion de tratamiento antifibrotico.
WO2015138761A3 (en) Methods for treating peripheral nerve damage
MX2020005471A (es) Compuestos para el tratamiento de trastornos neuromusculares.
EA201790430A1 (ru) С-20 стероидные соединения, композиции и их применение для лечения травматического повреждения головного мозга (tbi), включая сотрясения мозга
MX2020005398A (es) Compuestos para el tratamiento de trastornos neuromusculares.
PH12015502304A1 (en) Use of pidotimod to treat irritable bowel syndrome